Kraft Group is among the investors in the biopharmaceutical company's first funding round.

The pharmaceutical company, which is developing treatments for disorders including neuropathic pain and Crohn's Disease, is backed by investors including AbbVie.

Mobile healthcare technology company Wellframe has taken its financing this year to $10m after closing a Formation 8-backed series A round.

The Kaiser Permanente-backed governance, risk and compliance software producer has now secured about $130m in total.

Liverpool University is spinning out a new company that can make insoluble chemicals dissolve in water.

Oxford is spinning out Enhanced Medical to exploit new ultrasound imaging technology.

LionBird leads $4.6m series A into Chicago's PhysIQ life sciences spin-out.

Pharmaceutical company Chiesi Group has launched a corporate venture capital fund, Chiesi Ventures, targeting companies focusing on the treatment of rare diseases.

Clearside Biomedical has raised $16m in a series B round featuring pharmaceutical company Santen and RusnanoMedInvest, for the development of treatments for blinding diseases of the eye.